<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04163848</url>
  </required_header>
  <id_info>
    <org_study_id>2020-1971</org_study_id>
    <nct_id>NCT04163848</nct_id>
  </id_info>
  <brief_title>CARbon Impact of aNesthesic Gas</brief_title>
  <acronym>CARING</acronym>
  <official_title>CARbon Impact of aNesthesic Gas - A Carbon Footprint Comparison of Sevoflurane and Desflurane in an Optimized Fresh Gas Flow Protocol</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Ciusss de L'Est de l'Île de Montréal</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Ciusss de L'Est de l'Île de Montréal</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Assessing the impact of anesthesia practice on global warming and carbon footprint becomes&#xD;
      part of the standard of care and is growing concern within the anesthesia community. Global&#xD;
      Warming Potential (GWP) is a measure of how much a given mass of greenhouse gas contributes&#xD;
      to global warming over a specified time period. Inhaled anesthetics have various GWP20: 349&#xD;
      for sevoflurane and 3714 for desflurane. However, GWP20 and CDE20 alone are not sufficient to&#xD;
      evaluate the environmental impact of anesthetic gases. Other parameters must be included in&#xD;
      the analysis: fresh gas flow (FGF), carrier gas (air, O2, N2O) and potency of the anesthetic&#xD;
      gas. Unfortunately, the majority of trials did not fully consider the FGF reduction and the&#xD;
      fact that desflurane can be administered with new closed or very low-flow anesthesia circuits&#xD;
      as opposed as the recommended 2L/min that must be used for sevoflurane according to its&#xD;
      monography in Canada. Most of the calculations were made on a purely theoretical approach&#xD;
      that could be different from actual measurements based on a strictly monitored anesthesia&#xD;
      practice. When continuous and accurate gas monitoring and analysis is used as recommended&#xD;
      nowadays, the use of closed or semi-closed-circuit anesthesia with very low FGF might allow&#xD;
      for a reduction of more than 80% of the anesthetic gas administration and its consequent&#xD;
      pollution. By properly monitoring the anesthesia depth and analgesia adequacy, the&#xD;
      investigators can reduce the gas consumption. The proposed study will aim at determining&#xD;
      whether with the help of high-quality monitoring (BIS and NOL) and high-end ventilators that&#xD;
      allow minimal fresh gas flow, the use of desflurane remains more polluting than sevoflurane.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">September 25, 2019</start_date>
  <completion_date type="Actual">January 23, 2020</completion_date>
  <primary_completion_date type="Actual">January 23, 2020</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Other</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>CO2 equivalent of volatile inhaled anesthesic gases use in grams</measure>
    <time_frame>From intubation to end of surgery</time_frame>
    <description>To compare total volatile inhaled anesthetics consumption in CO2 equivalent (grams) per hour during anesthesia for laparoscopic surgery between two groups: Group &quot;D&quot; for Desflurane and group &quot;S&quot; for Sevoflurane</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Total volatile inhalated anesthesics consumption in mL</measure>
    <time_frame>From intubation to end of surgery</time_frame>
    <description>To compare the total volatile inhaled anesthetics consumption in mL, mL/h and mL/kg/h during anesthesia for laparoscopic surgery between desflurane and sevoflurane</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cost in dollars</measure>
    <time_frame>From intubation to end of surgery</time_frame>
    <description>To compare the total cost of volatile inhalated anesthesics (mL of gaz x $/mL of gaz) for each group</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Extubation time in minutes</measure>
    <time_frame>From stopping anesthesics gases to extubation</time_frame>
    <description>To compare the extubation time</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Recovery room time in minutes</measure>
    <time_frame>From end of surgery to 240minutes post-surgery</time_frame>
    <description>To compare the time spent in the recovery room</description>
  </secondary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Actual">58</enrollment>
  <condition>Gas; Inhalation</condition>
  <condition>Anesthesia</condition>
  <arm_group>
    <arm_group_label>Desflurane</arm_group_label>
    <description>desflurane administration based on a BIS index kept between 40-60 and with use of the semi-closed circuit of the Draeger A500 ventilator and its econometer for an optimized fresh gas flow as low as the O2 consumption allows</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Sevoflurane</arm_group_label>
    <description>sevoflurane administration based on a BIS kept between 40-60 and with use of the semi-closed circuit of the Draeger A500 ventilator with a fixed fresh gas flow of 2L/min as requested in the gas monography</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Pollution</intervention_name>
    <description>CO2 equivalent productions related to anesthetic gases use during general anesthesia for laparoscopic surgery</description>
    <arm_group_label>Desflurane</arm_group_label>
    <arm_group_label>Sevoflurane</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        General population undergoing laparoscopic gynecologic, urologic or general surgery&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  ASA 1-3 patients,&#xD;
&#xD;
          -  laparoscopic general, gynecological or urologic surgery requiring general anesthesia&#xD;
             without additional regional anesthesia technique&#xD;
&#xD;
          -  fully consented,&#xD;
&#xD;
          -  BMI &lt; 40,&#xD;
&#xD;
          -  age &gt; 18yo,&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  post-operative need for a neuraxial or regional analgesic technique&#xD;
&#xD;
          -  history of active coronary artery disease&#xD;
&#xD;
          -  serious cardiac arrhythmia (including atrial fibrillation)&#xD;
&#xD;
          -  history of substance abuse&#xD;
&#xD;
          -  chronic use of psychotropic and/or opioid drugs&#xD;
&#xD;
          -  history of psychiatric diseases with the need of medication&#xD;
&#xD;
          -  history of refractory PONV&#xD;
&#xD;
          -  allergy or contra-indication to any drug used in the study protocol&#xD;
&#xD;
          -  refusal of the patient for participation in the study&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Hôpital Maisonneuve-Rosemont, CIUSSS de l'Est de l'Ile de Montréal</name>
      <address>
        <city>Montréal</city>
        <state>Quebec</state>
        <zip>H1T2M4</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <verification_date>January 2021</verification_date>
  <study_first_submitted>November 6, 2019</study_first_submitted>
  <study_first_submitted_qc>November 12, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">November 15, 2019</study_first_posted>
  <last_update_submitted>January 26, 2021</last_update_submitted>
  <last_update_submitted_qc>January 26, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">January 27, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Ciusss de L'Est de l'Île de Montréal</investigator_affiliation>
    <investigator_full_name>Olivier Verdonck</investigator_full_name>
    <investigator_title>Assistant Professor, Deputy chief of the Department of Anesthesiology of Maisonneuve-Rosemont Hospital, University of Montreal(UDeM)</investigator_title>
  </responsible_party>
  <keyword>Desflurane</keyword>
  <keyword>Sevoflurane</keyword>
  <keyword>Fresh gas flow</keyword>
  <keyword>Environment</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Respiratory Aspiration</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

